

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Addr ss: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
08/279,275	07/22/94	WEINER		Н	101016104US1
_		18N2/1208	コ	EXAMINER	
DARBY & DARE	3Y	do Tool E TERNO E - do rive Tel Tel		ACHUTAMURTHY, P	
805 THIRD AV	/E.			ART UNIT	PAPER NUMBER
NEW YORK NY	10022			1818 DATE MAILED	52

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Office Action Summary

Application No. 08/279,275

Applicant(s)

Examiner

Group Art Unit

Weiner et al

P. Achutamurthy

1818

X Responsive to communication(s) filed on Oct 12, 1997	
☐ This action is FINAL .	
Since this application is in condition for allowance except for in accordance with the practice under <i>Ex parte Quayle</i> , 1935	
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure tapplication to become abandoned. (35 U.S.C. § 133). Extensic 37 CFR 1.136(a).	to respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	
☐ Claim(s)	
☐ Claims	
Application Papers	
☐ See the attached Notice of Draftsperson's Patent Drawing	g Review, PTO-948.
☐ The drawing(s) filed on is/are object	ed to by the Examiner.
☐ The proposed drawing correction, filed on	is □approved □disapproved.
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
☐ Acknowledgement is made of a claim for foreign priority	under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of	the priority documents have been
☐ received.	
received in Application No. (Series Code/Serial Num	
\square received in this national stage application from the	International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priorit	y under 35 U.S.C. § 119(e).
Attachment(s)	
□ Notice of References Cited, PTO-892	.1-1 47 40
	o(s). <u>47, 48</u>
☐ Interview Summary, PTO-413☐ Notice of Draftsperson's Patent Drawing Review, PTO-94	8
☐ Notice of Informal Patent Application, PTO-152	•
, re	
SEE OFFICE ACTION ON T	HE FOLLOWING PAGES

52



Serial Number: 08/279,275

Art Unit: 1818

DETAILED ACTION

Since this application is eligible for the transitional procedure of 37 CFR 1.129(a), and the fee set forth in 37 CFR 1.17(r) has been timely paid, the finality of the previous Office action is hereby withdrawn pursuant to 37 CFR 1.129(a). Applicant's FIRST submission after final filed on October 12, 1997 has been entered.

Rejections A and C issued in the Office action of 12/11/96 (paper No. 44) are hereby withdrawn in view of the amendment to the claims and applicant's arguments.

However Rejection B (under 35 USC § 112, first paragraph) of claims 1, 2, 9, 11-13, 15-18, as further applied to new claims 21-24, and 26 is maintained for the reasons of record I paper no. 44.

Response to Arguments

Applicant's arguments filed October 12, 1997 have been fully considered but they are not persuasive.

The Declaration of Dr. Weiner filed October 12, 1997 is acknowledged and appreciated. Both the applicants arguments in the response and the Declaration have been carefully considered but they are not convincing. The arguments are mainly based on the general mechanisms involved in the effect of autoantighens on T-cell responses in autoimmune diseases and several autoantigens have been demonstrated to be effective in treating corresponding autoimmune diseases by the oral administration of the autoantigens. However, as has been maintained before,

Page 3

Serial Number: 08/279,275

Art Unit: 1818

although a general mechanism may be involved in the T-cell mediated responses in an autoimmune disease, there a wide number of autoimmune diseases with divergent etiologies and specific symptoms, demonstration of the oral efficacy of few selected autoantigens is not believed to provide sufficient evidence to warrant patentability of the instant claims which are generically drawn to treatment of any autoimmune disease with a corresponding autoantigen or its fragments.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to P,. Achutamurthy whose telephone number is (703) 308-3804. The examiner can normally be reached on Monday-Thursday from 7:00 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Donald E. Adams, Ph.D., can be reached on (703) 308-0570. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

December 7, 1997

PRIMARY EXAMINER

GROUP 1800